1. Administration for a minimum of 12 weeks, and a stable dose for at least 56 days (8 weeks prior to signing consent) of the following permitted steroid sparing agents: Azathioprine, mycophenolate mofetil or mycophenolic acid, chloroquine, hydroxychloroquine, or methotrexate